



SEQUENCE LISTING

<110> DINGIVAN, CHRISTINE

<120> METHODS OF PREVENTING OR TREATING INFLAMMATORY OR AUTOIMMUNE
DISORDERS BY ADMINISTERING CD2 ANTAGONISTS IN COMBINATION WITH OTHER
PROPHYLACTIC OR THERAPEUTIC AGENTS

<130> 10271-063

<140> 10/091,313

<141> 2002-03-04

<150> 60/273,098

<151> 2001-03-02

<150> 60/346,918

<151> 2001-10-19

<160> 13

<170> PatentIn version 3.1

<210> 1

<211> 5

<212> PRT

<213> Mus sp.

<400> 1

Glu Tyr Tyr Met Tyr
1 5

<210> 2

<211> 17

<212> PRT

<213> Mus sp.

<400> 2

Arg Ile Asp Pro Glu Asp Gly Ser Ile Asp Tyr Val Glu Lys Phe Lys
1 5 10 15

Lys

<210> 3

<211> 9

<212> PRT

<213> Mus sp.

<400> 3

Gly Lys Phe Asn Tyr Arg Phe Ala Tyr
1 5

<210> 4

<211> 16

<212> PRT

<213> Mus sp.

<400> 4

Arg Ser Ser Gln Ser Leu Leu His Ser Ser Gly Asn Thr Leu Asn Trp
1 5 10 15

<210> 5
 <211> 7
 <212> PRT
 <213> Mus sp.

<400> 5
 Leu Val Ser Lys Leu Glu Ser
 1 5

<210> 6
 <211> 9
 <212> PRT
 <213> Mus sp.

<400> 6
 Met Gln Phe Thr His Tyr Pro Tyr Thr
 1 5

<210> 7
 <211> 347
 <212> PRT
 <213> Homo Sapiens

<400> 7
 Met Val Ala Gly Ser Asp Ala Gly Arg Ala Leu Gly Val Leu Ser Val
 1 5 10 15

Val Cys Leu Leu His Cys Phe Gly Phe Ile Ser Cys Phe Ser Gln Gln
 20 25 30

Ile Tyr Gly Val Val Tyr Gly Asn Val Thr Phe His Val Pro Ser Asn
 35 40 45

Val Pro Leu Lys Glu Val Leu Trp Lys Lys Gln Lys Asp Lys Val Ala
 50 55 60

Glu Leu Glu Asn Ser Glu Phe Arg Ala Phe Ser Ser Phe Lys Asn Arg
 65 70 75 80

Val Tyr Leu Asp Thr Val Ser Gly Ser Leu Thr Ile Tyr Asn Leu Thr
 85 90 95

Ser Ser Asp Glu Asp Glu Tyr Glu Met Glu Ser Pro Asn Ile Thr Asp
 100 105 110

Thr Met Lys Phe Phe Leu Tyr Val Asp Lys Thr His Thr Cys Pro Pro
 115 120 125

Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro
 130 135 140

Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr
 145 150 155 160

Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn
 165 170 175

Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg
 180 185 190

Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val		
		195					200					205					
Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser		
		210				215					220						
Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys		
		225			230					235					240		
Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Asp		
				245					250					255			
Glu	Leu	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe		
			260					265					270				
Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu		
		275					280					285					
Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe		
		290				295					300						
Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly		
		305			310				315						320		
Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu	His	Asn	His	Tyr		
				325					330					335			
Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys							
			340					345									

<210> 8

<211> 5

<212> PRT

<213> Mus sp.

<400> 8

Ser Tyr Asp Met Ser
1 5

<210> 9

<211> 7

<212> PRT

<213> Mus sp.

<400> 9

Lys Val Ser Ser Gly Gly Gly
1 5

<210> 10

<211> 8

<212> PRT

<213> Mus sp.

<400> 10

His Asn Tyr Gly Ser Phe Ala Tyr
1 5

<210> 11

<211> 11

<212> PRT
<213> Mus sp.

<400> 11
Gln Ala Ser Gln Ser Ile Ser Asn His Leu His
1 5 10

<210> 12
<211> 7
<212> PRT
<213> Mus sp.

<400> 12
Tyr Arg Ser Gln Ser Ile Ser
1 5

<210> 13
<211> 9
<212> PRT
<213> Mus sp.

<400> 13
Gln Gln Ser Gly Ser Trp Pro His Thr
1 5